AN2 Therapeutics, Inc.

MENLO PARK, Calif. --(BUSINESS WIRE)--Sep. 16, 2026-- AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced it granted inducement equity awards to Cameron Trenor, The post AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4) appeared first on AN2 Therapeutics.

Abstracts highlight epetraborole’s potential beneficial effects on hematological profile across clinical and nonclinical studies MENLO PARK, Calif. --(BUSINESS WIRE)--Aug. 31, 2026-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and The post AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting appeared first on AN2 Therapeutics.

Dr. Trenor brings more than two decades of clinical, translational and drug development leadership experience advancing innovative therapies across rare diseases, hematology and oncology MENLO PARK, Calif. --(BUSINESS WIRE)--Aug. 24, 2026-- AN2 Therapeutics, Inc. The post AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer appeared first on AN2 Therapeutics.

Expanding Phase 2 study start-up activities to support global trial of oral epetraborole in polycythemia vera Enrollment ongoing in Phase 2 investigator-initiated trial of epetraborole for M. abscessus lung disease Positive non-human primate efficacy and favorable Phase 1 clinical pharmacokinetics The post AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights appeared first on AN2 Therapeutics.

Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humans Phase 1 First-In-Human (FIH) study showed favorable safety and tolerability profile; no dose-limiting toxicities The post AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease appeared first on AN2 Therapeutics.

MENLO PARK, Calif. --(BUSINESS WIRE)--May 21, 2026-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will present at the The post AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference appeared first on AN2 Therapeutics.

Oral epetraborole program in polycythemia vera advancing toward Phase 2 Phase 2 investigator-initiated trial with epetraborole for M. abscessus lung disease underway Data expected in 2Q/2026 from two studies of oral AN2-502998, under development for chronic Chagas disease: a Phase 1 first-in-human The post AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights appeared first on AN2 Therapeutics.

MENLO PARK, Calif. --(BUSINESS WIRE)--May 7, 2026-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in The post AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum appeared first on AN2 Therapeutics.

MENLO PARK, Calif. --(BUSINESS WIRE)--Mar. 31, 2026-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the initiation of a Phase 2 investigator-initiated clinical The post AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease appeared first on AN2 Therapeutics.

Phase 2 study of oral epetraborole in polycythemia vera (PV) expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027 Advancing Phase 2 investigator-initiated trial of epetraborole in M. abscessus complex lung disease; Enrollment expected to begin in 1Q26 with The post AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights appeared first on AN2 Therapeutics.